Performance outcome assessments in MS clinical trials are more sensitive to disease progression and treatment effects than clinical assessments
Wallace W. Tourtellotte, Karl Syndulko, Robert W. BaumhefnerVolume:
56-63
Year:
1995
Language:
english
DOI:
10.1016/0165-5728(95)99040-p
File:
PDF, 159 KB
english, 1995